ER-Positive HER2-Negative Advanced Breast Cancer Resistant To Adjuvant Endocrine Therapy
RHHBYRoche HoldingCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Giredestrant (Estrogen Receptor Degrader) in ER-Positive HER2-Negative Advanced Breast Cancer Resistant To Adjuvant Endocrine Therapy. The expected timing is based on the latest available company guidance and may change.
02/19/26:- Phase 3 pionERA trial evaluating giredestrant plus CDK4/6 inhibitor in endocrine-resistant ER+ HER2- advanced breast cancer is ongoing. 03/08/26:- Ph3 pionERA endocrine-resistant ER+ HER2- breast cancer readout expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.